Bayer AG, Germany’s largest drugmaker, plans to buy all remaining shares it doesn’t already own in Schering AG, after increasing its stake to more than 95% as part of a €17 billion ($21.5 billion) takeover. Bayer bought more Schering shares on the stock market yesterday, the Leverkusen, Germany-based company said in an e-mailed statement on Saturday. “We will now arrange a further meeting of Schering shareholders as soon as possible to finalize the full takeover,” Michael Schade, a spokesman for Bayer, said by telephone from Leverkusen. In Germany, a holding of 95% or more in a company gives the investor the right to buy all remaining shares. Bayer bought Berlin-based Schering to acquire the company’s best-selling multiple sclerosis treatment and Yasmin contraceptive pills to bolster its health-care unit. Schering will hold a shareholders meeting on September 13, at which Bayer plans to win approval for an accord to get full operational control of the company and all its profits, so-called domination, and profit and loss transfer agreements. (Bloomberg)